REVIEW PAPER
Application of biological agents for treatment of patients with systemic lupus erythematosus
Online publication date: 2011-08-30
Reumatologia 2011;49(4):264-274
KEYWORDS
ABSTRACT
Systemic lupus erythematosus is an autoimmune disorder of unknown aetiology. High efficacy of biological agents in patients with rheumatoid arthritis suggests investigations on similar medication applicable in the management of systemic lupus erythematosus. Several antibodies were investigated including those against soluble B-lymphocyte-stimulating factor, BLyS (B lymphocyte stimulator) (belimubab, briobacept, atacicept), against B cells (rituximab, ocrelizumab, epratuzumab), inhibiting co-stimulation of T cells (abatacept), tolerogens, interferon and others. Despite some beneficial effects, none of the investigated agents is recommended for clinical practice.
REFERENCES (56)
1.
Moisini I, Davidson A. BAFF: a local and systemic target in autoimmune diseases. Clin Exp Immunol 2009; 158: 155-163. .
2.
Petri M, Stohl W, Chatham W, et al. Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus. Arthritis Rheum 2008; 58: 2453-2459. .
3.
Wallace DJ, Stohl W, Furie RA, et al. A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum 2009; 61: 1168-1178. .
4.
Jacobi AM, Huang W, Wang T, et al. Effect of long-term belimumab treatment on B cells in systemic lupus erythematosus: extension of a phase II, double-blind, placebo-controlled, dose-ranging study. Arthritis Rheum 2010; 62: 201-210. .
5.
Merrill JT, Wallace DJ, McKay J, et al. Long-term safety profile of belimumab (fully human monoclonal antibody to BLys) in patients with systemic lupus erythematosus (SLE). Ann Rheum Dis 2008; 67: 217. .
6.
Dall’Era M, Chakravarty E, Wallace D, et al. Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial. Arthritis Rheum 2007; 56: 4142-4150. .
7.
Tokunaga M, Saito K, Kawabata D, et al. Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system. Ann Rheum Dis 2007; 66: 470-475. .
8.
Chehab G, Sander O, Fischer-Betz R, Schneider M. Anti-CD20 therapy for inducing and maintaining remission in refractory systemic lupus erythematosus. Z Rheumatol 2007; 66: 328, 330-336. .
9.
Looney RJ, Anolik JH, Campbell D, et al. B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum 2004; 50: 2580-2589. .
10.
Lindholm C, Börjesson-Asp K, Zendjanchi K, et al. Longterm clinical and immunological effects of anti-CD20 treatment in patients with refractory systemic lupus erythematosus. J Rheumatol 2008; 35: 826-833. .
11.
Gunnarsson I, Sundelin B, Jónsdóttir T, et al. Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis. Arthritis Rheum 2007; 56: 1263-1272. .
12.
van Vollenhoven RF, Gunnarsson I, Welin-Henriksson E, et al. Biopsy-verified response of severe lupus nephritis to treatment with rituximab (anti-CD20 monoclonal antibody) plus cyclophosphamide after biopsy-documented failure to respond to cyclophosphamide alone. Scand J Rheumatol 2004; 33: 423-427. .
13.
Pepper R, Griffith M, Kirwan C, et al. Rituximab is an effective treatment for lupus nephritis and allows a reduction in maintenance steroids. Nephrol Dial Transplant 2009; 24: 3717-3723. .
14.
Armstrong DJ, McCarron MT, Wright GD. SLE-associated transverse myelitis successfully treated with Rituximab (anti-CD20 monoclonal antibody). Rheumatol Int 2006; 26: 771-772. .
15.
Smith KG, Jones RB, Burns SM, Jayne DR. Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: Remission, relapse, and re-treatment. Arthritis Rheum 2006; 54: 2970-2982. .
16.
Niaz FA, Aleem A. Response to rituximab in a refractory case of thrombotic thrombocytopenic purpura associated with systemic lupus erythematosus. Saudi J Kidney Dis Transpl 2010; 21: 109-112. .
17.
Kamiya K, Kurasawa K, Arai S, et al. Rituximab was effective on refractory thrombotic thrombocytopenic purpura but induced a flare of hemophagocytic syndrome in a patient with systemic lupus erythematosus. Mod Rheumatol 2010; 20: 81-85. .
18.
Hundae A, Peskoe S, Grimsley E, Patel S. Rituximab therapy for refractory thrombotic thrombocytopenic purpura and autoimmune-mediated thrombocytopenia in systemic lupus erythematosus. South Med J 2008; 101: 943-944. .
19.
Lehembre S, Macario-Barrel A, Musette P, et al. Rituximab treatment for immune thrombocytopenia associated with systemic lupus erythematosus. Ann Dermatol Venereol 2006; 133: 53-55. .
20.
Perrotta S, Locatelli F, La Manna A, et al. Anti-CD20 monoclonal antibody (Rituximab) for life-threatening autoimmune haemolytic anaemia in a patient with systemic lupus erythematosus. Br J Haematol 2002; 116: 465-467. .
21.
Risselada AP, Kallenberg CG. Therapy-resistent lupus skin disease successfully treated with rituximab. Rheumatology (Oxford) 2006; 45: 915-916. .
22.
Pego-Reigosa JM, Lu TY, Fontanillo MF, et al. Long-term improvement of lipid profile in patients with refractory systemic lupus erythematosus treated with B-cell depletion therapy: a retrospective observational study. Rheumatology (Oxford) 2010; 49: 691-696. .
23.
Hickman RA, Denniston AK, Yee CS, et al. Bilateral retinal vasculitis in a patient with systemic lupus erythematosus and its remission with rituximab therapy. Lupus 2010; 19: 327-329. .
24.
Todd DJ, Costenbader KH. Dyspnoea in a young woman with active systemic lupus erythematosus. Lupus 2009; 18: 777-784. .
25.
Kittaka K, Dobashi H, Baba N, et al. A case of Evans syndrome combined with systemic lupus erythematosus successfully treated with rituximab. Scand J Rheumatol 2008; 37: 390-393. .
26.
Ahn ER, Lander G, Bidot CJ, et al. Long-term remission from life-threatening hypercoagulable state associated with lupus anticoagulant following rituximab therapy. Am J Hematol 2005; 78: 127-129. .
27.
Petschner F, Walker UA, Schmitt-Gräff A, et al. “Catastrophic systemic lupus erythematosus” with Rosai-Dorfman sinus histiocytosis. Successful treatment with anti-CD20/rutuximab. Dtsch Med Wochenschr 2001; 126: 998-1001. .
28.
Lim SW, Gillis D, Smith W, et al. Rituximab use in systemic lupus erythematosus pneumonitis and a review of current reports. Intern Med J 2006; 36: 260-262. .
29.
Torrente-Segarra V, Lisbona-Pérez M, Rotes-Sala D, et al. Clinical, biological and ultrasonographic remission in a patient with musculoskeletal systemic lupus erythematosus with rituximab. Lupus 2009; 18: 270-272. .
30.
Polido-Pereira J, Ferreira D, Rodrigues AM, et al. Rituximab use in pediatric autoimmune diseases: four case reports. Ann N Y Acad Sci 2009; 1173: 712-720. .
31.
Podolskaya A, Stadermann M, Pilkington C, et al. B cell depletion therapy for 19 patients with refractory systemic lupus erythematosus. Arch Dis Child 2008; 93: 401-406. .
32.
Marks SD, Tullus K. Modern therapeutic strategies for paediatric systemic lupus erythematosus and lupus nephritis. Acta Paediatr 2010; 99: 967-974. .
33.
Ramos-Casals M, Brito-Zerón P, Mun~oz S, Soto MJ; BIOGEAS STUDY Group. A systematic review of the off-label use of biological therapies in systemic autoimmune disease. Medicine 2008; 87: 345-364. .
34.
Lu TY, Ng KP, Cambridge G, et al. A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: the first fifty patients. Arthritis Rheum 2009; 61: 482-487. .
35.
Leandro MJ, Cambridge G, Edwards JC, et al. B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients. Rheumatology (Oxford) 2005; 44: 1542-1545. .
36.
Leandro MJ, Edwards JC, Cambridge G, et al. An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum 2002; 46: 2673-2677. .
37.
Merrill JT, Neuwelt CM, Wallace DJ, et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 2010; 62: 222-233. .
38.
Terrier B, Amoura Z, Ravaud P, et al. Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French Autoimmunity and Rituximab registry. Arthritis Rheum 2010; 62: 2458-2466. .
39.
Study to Evaluate Ocrelizumab in Patients With Nephritis Due to Systemic Lupus Erythematosus (BELONG) Clinical trials.com .
40.
Study to Evaluate Two Doses of Ocrelizumab in Patients With Active Systemic Lupus Erythematosus (BEGIN) Clinical trials.com .
41.
Petri M, et al. Clinically meaningful improvements with epratuzumab (anti-CD22 mAb targeting B-cells) in patients (Pts) with moderate/severe SLE flares: results from 2 randomized controlled trials. Arthritis Rheum 2008; 58 (Suppl 9): S571. American College of Rheumatology (ACR) Annual Scientific Meeting, October 24-29, 2008; San Francisco, USA. .
42.
Yazawa N, Hamaguchi Y, Poe JC, Tedder TF. Immunotherapy using unconjugated CD19 monoclonal antibodies in animal models for B lymphocyte malignancies and autoimmune disease. Proc Natl Acad Sci USA 2005; 102: 15178-15183. .
43.
Merrill JT, Burgos-Vargas R, Westhovens R, et al. The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2010; 62: 3077-3087. .
44.
Cardiel MH, Tumlin JA, Furie RA, et al. Abetimus sodium for renal flare in systemic lupus erythematosus: results of a randomized, controlled phase III trial. Arthritis Rheum 2008; 58: 2470-2480. .
45.
Niewold TB, Swedler WI. Systemic lupus erythematosus arising during interferon-alpha therapy for cryoglobulinemic vasculitis associated with hepatitis C. Clin Rheumatol 2005; 24: 178-181. .
46.
Ioannou Y, Isenberg DA. Current evidence for the induction of autoimmune rheumatic manifestations by cytokine therapy. Arthritis Rheum 2000; 43: 1431-1442. .
47.
Niewold TB, Hua J, Lehman TJ, et al. High serum IFN- activity is a heritable risk factor for systemic lupus erythematosus. Genes Immun 2007; 8: 492-502. .
48.
Yao Y, Richman L, Higgs BW, et al. Neutralization of interferon-alpha/beta-inducible genes and downstream effect in a phase I trial of an antiinterferon-alpha monoclonal antibody in systemic lupus erythematosus. Arthritis Rheum 2009; 60: 1785-1796. .
49.
Illei GG, Shirota Y, Yarboro CH, et al. Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study. Arthritis Rheum 2010; 62: 542-552. .
50.
Matsumura R, Umemiya K, Sugiyama T, et al. Anti-tumor necrosis factor therapy in patients with difficult-to-treat lupus nephritis: a prospective series of nine patients. Clin Exp Rheumatol 2009; 27: 416-421. .
51.
Takahashi N, Naniwa T, Banno S. Successful use of etanercept in the treatment of acute lupus hemophagocytic syndrome. Mod Rheumatol 2008; 18: 72-75. .
52.
Aringer M, Graninger WB, Steiner G, Smolen JS. Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study. Arthritis Rheum 2004; 50: 3161-3169. .
53.
Aringer M, Steiner G, Graninger WB, et al. Effects of short-term infliximab therapy on autoantibodies in systemic lupus erythematosus. Arthritis Rheum 2007; 56: 274-279. .
54.
Uppal SS, Hayat SJ, Raghupathy R. Efficacy and safety of infliximab in active SLE: a pilot study. Lupus 2009; 18: 690-697. .
55.
Aringer M, Houssiau F, Gordon C, et al. Adverse events and efficacy of TNF-αlpha blockade with infliximab in patients with systemic lupus erythematosus: long-term follow-up of 13 patients. Rheumatology (Oxford) 2009; 48: 1451-1454. .
56.
Soforo E, Baumgartner M, Francis L, et al. Induction of systemic lupus erythematosus with tumor necrosis factor blockers. J Rheumatol 2010; 37: 204-205.
Copyright: © Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (https://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Share
RELATED ARTICLE
| eISSN: | 2084-9834 |
| ISSN: | 0034-6233 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
